legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

## Editas Medicine, Inc. Conference Call and Webcast

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a conference call and webcast scheduled for Wednesday, May 8, 2024, at 8:00 a.m. ET. The purpose of the call is to discuss the results for the first quarter of 2024 and provide a corporate update.

### How AI legalese decoder Can Help

AI legalese decoder can assist in simplifying the legal jargon often associated with gene editing companies like Editas Medicine, Inc. By using AI technology to break down complex legal terms and terms specific to the healthcare industry, users can gain a better understanding of the information being presented during the conference call and webcast.

Participating in the call is easy, as U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the scheduled start time. Participants should request to be connected to the Editas Medicine Earnings Conference Call.

The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available on the same site about an hour after the call concludes.

In addition to the conference call, management will take part in the 2024 RBC Capital Markets Global Healthcare Conference in a fireside chat format on Wednesday, May 15, at 2:05 p.m. ET in New York, NY. The fireside chat will be webcast and can be accessed through the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following each event.

## About Editas Medicine

Editas Medicine is a clinical-stage gene editing company striving to utilize the power of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems to develop treatments for individuals with serious diseases globally. The company aims to create, produce, and market transformative, precise genomic medicines for a wide range of diseases. Editas Medicine holds the exclusive license for the Broad Institute’s Cas12a patent estate and the Cas9 patent estates of Broad Institute and Harvard University for human medicines. For more current information and scientific presentations, please visit www.editasmedicine.com.

For any media or investor-related inquiries, please contact Cristi Barnett at (617) 401-0113 or [email protected].

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link